You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Prevention of IMD

  • CDC (Centers for Disease Controls and Prevention) advises that the best defense against meningococcal disease is to keep up to date with recommended immunisations. Additionally, healthy lifestyle as well as not coming into close contact with people who are sick can also help. 1
  • BEXSERO is currently the first and only MenB vaccine from the age of 2 months to demonstrate potential coverage of the majority of MenB strains in Europe.* 2 3 4
  • BEXSERO can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines:
    diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, hepatitis B, heptavalent pneumococcal conjugate, measles, mumps, rubella, varicella and meningococcal groups A, C, W, Y conjugate.
    Concomitant administration of Bexsero
     with vaccines other than those mentioned above has not been studied.
    Due to an increased risk of fever, tenderness at the injection site, change in eating habits and irritability when Bexsero was co-administered with the above vaccines, separate vaccinations can be considered when possible.

*Strains collected from July 2007 to June 2008 across 5 European countries.

BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains and not all vaccine recipients will be protected from the disease 2


  1. CDC webpage: Meningococcal Home/About the Disease. Available from: Last accessed December 2016
  2. BEXSERO summary of product characteristics 
  3. Vogel U, et al., Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013:13(5): 416–425
  4. Medini D, Stella M, Wassil J, MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine, Vaccine, 2015;33(23):2629-2636

Prescription Only Medicine.
Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health

Trade marks are owned by or licensed to the GSK group of companies.
© 2020 GSK group of companies or its licensor.